Country Club Bank Buys 148,643 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Country Club Bank boosted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 112.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 280,716 shares of the company's stock after acquiring an additional 148,643 shares during the quarter. Country Club Bank owned about 0.06% of Elanco Animal Health worth $2,922,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ELAN. Steward Partners Investment Advisory LLC grew its position in Elanco Animal Health by 28.3% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company's stock worth $124,000 after buying an additional 2,264 shares during the period. Dimensional Fund Advisors LP increased its stake in Elanco Animal Health by 6.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after purchasing an additional 1,074,274 shares in the last quarter. Jones Financial Companies Lllp raised its holdings in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after purchasing an additional 2,059 shares during the last quarter. Yousif Capital Management LLC purchased a new stake in Elanco Animal Health during the first quarter worth $119,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in Elanco Animal Health in the first quarter valued at $111,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Performance

NYSE ELAN traded down $0.02 during trading hours on Monday, reaching $14.88. The company's stock had a trading volume of 3,824,811 shares, compared to its average volume of 5,373,032. The stock has a market cap of $7.39 billion, a PE ratio of 20.10, a PEG ratio of 2.91 and a beta of 1.67. The business has a 50-day simple moving average of $13.45 and a 200 day simple moving average of $11.69. Elanco Animal Health Incorporated has a 52 week low of $8.02 and a 52 week high of $15.78. The company has a current ratio of 2.71, a quick ratio of 1.46 and a debt-to-equity ratio of 0.68.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, beating the consensus estimate of $0.31 by $0.06. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. Elanco Animal Health had a net margin of 8.43% and a return on equity of 7.54%. Elanco Animal Health's revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.34 earnings per share. Equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ELAN. Wall Street Zen raised Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Finally, Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Four research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $15.33.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.